Recent Advances for Treating Anemia in Lower-Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, provides a brief overview of lower-risk myelodysplastic syndromes (LR-MDS).

A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.

An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.

Guillermo Garcia-Manero, MD, reviews recent results from the COMMANDS study investigating luspatercept versus epoetin alfa in patients with ESA-naïve, transfusion dependent LR-MDS.

A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.

Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.

Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.

A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.

An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.

Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.